/

NVN Liquidation, Inc.

NOVNQ US

NOVNQ USNVN Liquidation, Inc.

United States Composite

0.00

USD

+0.00

(-99.87%)

-1.35EPS Dil.

-NaNMarket Cap

Next Earnings

December 22

Held by Insiders

0.87%

Held by Institutions

0.50%

Short % of Float

1.37%

YTD Yield

-99.57%

3Y Yield

-99.96%

5Y Yield

-99.96%

Capital Structure

FRC

•

in mil. unless spec.

Sep'22

Dec'22

Mar'23

ST Debt

LT Borrowings

- -

LT Finance Leases

Preferred Equity and Hybrid Capital

- -

Shares Outstanding

Market Capitalization

Working Capital

FRC

•

in mil. unless spec.

Sep'22

Dec'22

Mar'23

Total Current Assets

Cash, Cash Equivalents & STI

Accounts Receivable, Net

Inventories

Total Current Liabilities

Payables & Accruals

ST Debt

Deferred Revenue

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years

5 years

1 year

Sales/Revenue/Turnover

- -

168.33%

700.00%

Net Income, GAAP

-NaN%

-14.79%

-3.33%

Free Cash Flow

-NaN%

-5.92%

-2.94%

Total Cash Common Dividend

- -

Total Equity

-NaN%

-122.94%

-72.22%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

2021

2022

2023

- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

2021

-0.60

-0.39

-0.34

-0.44

-1.74

2022

-0.71

-0.44

-0.25

-0.12

-1.42

2023

-0.54

- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

2021

- -

2022

- -

2023

- -

Company Description

Full Time Employees: 90
Sector: Healthcare
Industry: Biotechnology
Address: 4020 Stirrup Creek Drive Durham NC United States 27703
Website: www.novan.com
Business: NVN Liquidation, Inc., a medical dermatology company, focuses on developing and commercializing therapeutic products for skin diseases. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2. NVN Liquidation, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. The company was formerly known as Novan, Inc. and changed its name to NVN Liquidation, Inc. in October 2023. The company was incorporated in 2006 and is headquartered in Durham, North Carolina. On July 17, 2023, NVN Liquidation, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Company Description

Full Time Employees: 90
Sector: Healthcare
Industry: Biotechnology
Address: 4020 Stirrup Creek Drive Durham NC United States 27703
Website: www.novan.com
Business: NVN Liquidation, Inc., a medical dermatology company, focuses on developing and commercializing therapeutic products for skin diseases. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2. NVN Liquidation, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. The company was formerly known as Novan, Inc. and changed its name to NVN Liquidation, Inc. in October 2023. The company was incorporated in 2006 and is headquartered in Durham, North Carolina. On July 17, 2023, NVN Liquidation, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.